Claudia Zylberberg interviewed for ‘Marketing Matters’ on Sirius XM Business Radio

This past week, Akron Biotech’s CEO Claudia Zylberberg was interviewed for Marketing Matters, a Sirius XM Business Radio show. Dr. Zylberberg appeared on the November 1, 2017 show to discuss how Akron Biotechnology has leveraged offline opportunities together with their online presence to enhance their brand. Marketing Matters is hosted by Wharton Marketing Professor Barbara Kahn and

Proceedings from Regenerative Medicine Forum Workshop at the National Academies Released

On June 26, 2017, the National Academies of Sciences, Engineering and Medicine organized a workshop hosted by the Regenerative Medicine Forum afocused on manufacturing and quality aspects in cell therapies. Akron’s CEO, Dr. Claudia Zylberberg, co-chaired the workshop. This was a public event with the aim of discussing challenges and best practices associated with defining and measuring the quality

Akron participates in panel on human platelet lysate at AABB Annual Meeting

The 2017 Annual Meeting of the American Association of Blood Banks (AABB) took place from October 7 – 10, 2017 in San Diego, CA. Akron Biotechnology participated in a panel as part of the AABB/ISCT Joint Working Group, Pooled Human Platelet Lysate (pHPL) for Cell Therapies Manufacturing. The thrust for this meeting comes from the increasing prevalence and

Wearable textile bandage releases wound-healing drugs on demand

Multiple approaches have been described for achieving therapeutically-effective wound healing. Biological factors that induce stimulation of cells to trigger and enhance the healing process have been extensively studied, and recently, new approaches for their delivery have been the focus of a vast number of studies. Delivery issues inherent to wound dressings include the need to

Ancillary materials: now, more than ever, at the core of new cell therapies + Exclusive discount code for Phacilitate Cell & Gene therapy summit

Raw materials have been, and will continue to be, at the core of new sets of therapies coming out over the next decade. Why? Simply because they are either scarce or limited, such as off-the-clot AB serum, or because they encompass a high risk, which is the case for animal-derived components. For this type of materials, concerns

Vibrations replace media to induce differentiation of MSCs into bone tissue

Bone is the second most grafted tissue after blood – however, autologous grafts are in short supply and allogeneic grafts are associated with problems including rejection by the body and post-transplant complications. For that reason, much work has been put into optimizing existing and finding new ways for creating induced bone grafts through tissue engineering,

Reprogramming cells into induced pluripotent stem cells using antibodies one step closer

The reprogramming of differentiated stem cells into induced pluripotent stem cells (IPSCs) typically takes place via a set of transcription factors Oct4 (Pou5f1), Sox2, cMyc, and Klf4. While reprogramming can be induced by replacing these factors with miRNA, small molecules and alternative transcription factors, a new approach described a number of antibodies that can achieve reprogramming of mature stem cells. The work

Optogenetics: From injectable sensors to smartphone-controlled cells

First demonstrated in 2002, the principle of optogenetics has since been utilized to develop a variety of approaches for the light-actuated control of cell function, particularly in neuroscience research. The principle involves the engineering of cells to express a light-sensitive protein, typically an ion channel or a G protein-coupled receptor, followed by illumination with light